207 related articles for article (PubMed ID: 21180541)
21. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.
Dasarathy S; Dasarathy J; Khiyami A; Yerian L; Hawkins C; Sargent R; McCullough AJ
J Clin Gastroenterol; 2015 Feb; 49(2):137-44. PubMed ID: 24583757
[TBL] [Abstract][Full Text] [Related]
22. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
23. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
24. Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W; Tian W; Lin L; Xu X
Diabetes Res Clin Pract; 2020 Dec; 170():108487. PubMed ID: 33035599
[TBL] [Abstract][Full Text] [Related]
25. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Gastaldelli A; Harrison SA; Belfort-Aguilar R; Hardies LJ; Balas B; Schenker S; Cusi K
Hepatology; 2009 Oct; 50(4):1087-93. PubMed ID: 19670459
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
27. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial.
Eckard C; Cole R; Lockwood J; Torres DM; Williams CD; Shaw JC; Harrison SA
Therap Adv Gastroenterol; 2013 Jul; 6(4):249-59. PubMed ID: 23814606
[TBL] [Abstract][Full Text] [Related]
28. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.
Nelson A; Torres DM; Morgan AE; Fincke C; Harrison SA
J Clin Gastroenterol; 2009; 43(10):990-4. PubMed ID: 19448566
[TBL] [Abstract][Full Text] [Related]
29. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study.
Hajiaghamohammadi AA; Ziaee A; Oveisi S; Masroor H
Hepat Mon; 2012 Aug; 12(8):e6099. PubMed ID: 23087748
[TBL] [Abstract][Full Text] [Related]
30. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.
Aithal GP; Thomas JA; Kaye PV; Lawson A; Ryder SD; Spendlove I; Austin AS; Freeman JG; Morgan L; Webber J
Gastroenterology; 2008 Oct; 135(4):1176-84. PubMed ID: 18718471
[TBL] [Abstract][Full Text] [Related]
31. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Neuschwander-Tetri BA; Brunt EM; Wehmeier KR; Oliver D; Bacon BR
Hepatology; 2003 Oct; 38(4):1008-17. PubMed ID: 14512888
[TBL] [Abstract][Full Text] [Related]
32. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
33. [Effects of telmisartan on resistin expression in a rat model of nonalcoholic steatohepatitis and insulin resistance].
Zhang Q; Wang Y; Liu Y; Yang Q; Wang X; Wang Q; Zhang C; Wang B
Zhonghua Gan Zang Bing Za Zhi; 2015 Apr; 23(4):281-5. PubMed ID: 26133820
[TBL] [Abstract][Full Text] [Related]
34. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study.
Lee YM; Low HC; Lim LG; Dan YY; Aung MO; Cheng CL; Wee A; Lim SG; Ho KY
Gastrointest Endosc; 2012 Oct; 76(4):756-60. PubMed ID: 22840293
[TBL] [Abstract][Full Text] [Related]
35. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.
Houghton D; Thoma C; Hallsworth K; Cassidy S; Hardy T; Burt AD; Tiniakos D; Hollingsworth KG; Taylor R; Day CP; McPherson S; Anstee QM; Trenell MI
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):96-102.e3. PubMed ID: 27521509
[TBL] [Abstract][Full Text] [Related]
36. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
37. Patients with Nonalcoholic Fatty Liver Disease Have a Low Response Rate to Vitamin D Supplementation.
Dasarathy J; Varghese R; Feldman A; Khiyami A; McCullough AJ; Dasarathy S
J Nutr; 2017 Oct; 147(10):1938-1946. PubMed ID: 28814531
[No Abstract] [Full Text] [Related]
38. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
39. Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial.
Li J; Ng EH; Stener-Victorin E; Hu Z; Shao X; Wang H; Li M; Lai M; Xie C; Su N; Yu C; Liu J; Wu T; Ma H
Trials; 2017 Mar; 18(1):115. PubMed ID: 28274268
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
